Fresenius Medical Care North America (FMCNA), the world's largest provider of dialysis services, today introduced its newly branded Frenova Renal Research business, the only Phase I-IV drug and device clinical development partner dedicated exclusively to renal research.
Since 2001, Frenova, formerly known as the Clinical Studies Group at FMCNA, has supported sponsors and nephrologists conducting research specific to kidney disease and its comorbid conditions.
"Frenova is a new name, but the company is built on more than a decade of experience focused exclusively on the clinical development of new renal therapies largely developed using the world's largest dialysis treatment and research network," said Kurt Mussina, vice president and general manager of Frenova. Frenova provides access to a network comprising more than 390,000 pre-dialysis patients with chronic kidney disease (CKD) and 183,000 active dialysis patients with end stage renal disease (ESRD), as well as extensive resources of real-world clinical data collected over the past two decades.
These resources, combined with Frenova's bioinformatics and analytics capabilities, provide an unparalleled asset for biopharmaceutical and medical device companies seeking to assess protocol feasibility, optimize research site selection and/or conduct highly targeted patient recruitment activities.
"The sheer depth of our renal expertise and our access to patients, sites, investigators and data resources for both cross-sectional and longitudinal analyses are indispensable assets for renal clinical development programs," said Mussina. "Developing treatments to improve the quality of life for people with kidney disease has always been our singular objective. Our new identity as Frenova reflects that mission and will play a key role in furthering it," Mussina added.
Antibiotic activity altered by interaction with nanoplastics, new research shows